Reneo Pharmaceuticals, Inc. (RPHM)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$4.79

P/E Ratio

N/A

Market Cap

$63.93M

Mar 20, 2024Apr 24, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$0.00$10.00$20.00
  • RPHM
Description
Add to research

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company was founded by Michael G. Grey and Niall O'Donnell on September 22, 2014 and is headquartered in San Diego, CA.

Metrics
Add to research

Overview

  • HQIrvine, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerRPHM
  • Price$4.79-3.23%

Trading Information

  • Market cap$63.93M
  • Float63.68%
  • Average Daily Volume (1m)35,309
  • Average Daily Volume (3m)104,432
  • EPS-$3.95

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$52.67M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$53.93M
  • EVN/A
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.82
  • Debt/Equity1.04
Documents
Add to research
SEC Filings
8-K (2025-03-10)
8-K (2024-12-10)
8-K (2024-11-07)
8-K (2024-10-08)
8-K (2024-10-02)
8-K (2024-09-20)
8-K (2024-09-13)
8-K (2024-08-13)
8-K (2024-05-13)
8-K (2024-05-07)
8-K (2024-03-28)
8-K (2024-02-23)
8-K (2023-12-14)
8-K (2023-11-13)
8-K (2023-10-30)
8-K (2023-10-10)
8-K (2023-08-10)
8-K (2023-06-07)
8-K (2023-05-11)
8-K (2023-05-05)
8-K (2023-05-03)
8-K (2023-03-27)
8-K (2023-03-14)
8-K (2023-03-10)
8-K (2023-01-09)
10-Q (2024-11-07)
10-Q (2024-08-13)
10-Q (2024-05-07)
10-Q (2023-11-13)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2025-03-10)
10-K (2024-03-28)
10-K (2023-03-27)
Factset
Factset Business Description
Factset Street Account
Reneo Pharmaceuticals repurchases 576.4K shares at $7.64 per share from vTv Therapeutics - 8-K ($7.97, 0.00) (2023-11-01T14:14:02Z)
Reneo Pharmaceuticals reports Q3 EPS ($0.57) vs FactSet ($0.57) [7 est, ($0.66)-(0.37)] ($6.40, 0.00) (2023-11-13T12:44:05Z)
Reneo Pharmaceuticals initiated outperform at William Blair (2023-11-15T05:31:27Z)
Reneo Pharmaceuticals Announces last patient last visit in pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM) ($8.26, 0.00) (2023-10-09T11:51:56Z)